Uncategorized
RetroSense Therapeutics Raises $6 million in an Over-Subscribed Series B Financing to Advance Clinical Development of Lead Product RST-001 for Retinitis Pigmentosa
ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics has secured $6 million in a Series B financing to further investigate the use of gene therapy and optogenetics to restore vision.
